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SCIENTIFIC EDITORIAL
Colchicine in acute pericarditis: A new standard?
La colchicine fait-elle partie du traitement systématique des péricardites
aiguës ?
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Background
Acute pericarditis is a common disease; despite the lack of precise epidemiological data,
approximately 1% of hospitalized patients and 5% of patients admitted to emergency
departments for non-acute myocardial infarction chest pain exhibit acute pericarditis [1].
With acute pericarditis, some simple questions must be raised.
Is it idiopathic or viral pericarditis, or is there a need for an
extensive aetiological search?
In developed countries, idiopathic or viral pericarditis (IVP) is the most common ﬁnal
diagnosis in the immunocompetent patient and a more precise diagnosis is often not needed
[2]. However, in about 15—20% of cases, a speciﬁc cause must be ruled out: systemic
disease (usually autoimmune); tuberculosis; neoplasic pericarditis; or postcardiac injury
syndrome. A few clinical factors can suggest secondary pericarditis and therefore indicate
a need for a full aetiological search [1]: fever greater than 38 ◦C; subacute onset (symptoms
developing over several days or weeks); large pericardial effusion or tamponade; lack of
response to aspirin or non-steroidal anti-inﬂammatory drugs (NSAIDs) after at least 1 week;
and female sex.
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; IVP, idiopathic or viral pericarditis; NSAID, non-steroidal anti-inﬂammatory drug;
PPS, postpericardiotomy syndrome; RP, recurrent pericarditis.
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Finally, diagnostic tests for suspected pericarditis should
outinely include electrocardiography, echocardiography,
hest X-rays and simple biological tests (to search for
nﬂammation and myocardial lesions); in the absence of the
actors detailed above, an extensive aetiological search is
ot necessary [2,3].
hat is the evolution?
esults from analysis of a large registry published in 2007
1] are revealing: 453 patients (IVP 83%; mean age 52± 18
ears; men 55%) with acute pericarditis were followed up for
1 months on average. Complications were detected in 95
atients: tamponade (3.1%); constrictive pericarditis (1.5%);
nd, mostly, recurrences (18.3%). On multivariable analysis,
isk factors for complications were only female sex (hazard
atio [HR]: 1.65; 95% conﬁdence interval [CI]: 1.08—2.52),
arge pericardial effusion (HR: 2.51; 95% CI: 1.37—4.61)
nd failure of aspirin or NSAID treatment (HR: 5.50; 95%
I: 3.65—8.51). These results conﬁrm previous results
ublished by the same team [4]: among 300 consecutive
atients with acute pericarditis, 254 (85%) were at low risk
nd therefore not admitted to hospital. The protocol was
afe because no case of cardiac tamponade was observed.
The most troublesome complication is recurrence
15—50%), which has a strong negative impact on the quality
f life of patients. The aetiology and pathogenesis of idio-
athic acute recurrent pericarditis (RP) are controversial
nd seem to involve a mixture of infectious, autoimmune
nd autoinﬂammatory pathways [5]. Relapses may occur
ith reduced drug doses (incessant pericarditis) or at vary-
ng intervals after discontinuation of the treatment (RP).
n survey results [6] published in 2005 for 55 patients with
ecurrences, the mean recurrence number was 1.45/patient
range: 1—5). The only factor independently associated with
isk of recurrence was previous use of corticosteroids (odds
atio: 10.35; 95% CI: 4.46—23.99; P < 0.001). In a subsequent
tudy, elevated C-reactive protein after 1 week also seemed
o be a risk factor for recurrence [7].
hat treatment should we use?
ecause of the relative lack of randomized trials, the
anagement of pericardial diseases is largely empirical.
owever, European guidelines [3] were published in 2004,
nd a few teams —– mostly Italian —– are expanding our
nowledge on this subject.
Corticosteroid administration must be avoided in most
ases; indeed, as explained above, such administration is
risk factor for recurrence, and because the treatment is
ften prolonged, side effects are frequent [2,8]. However,
n systemic autoimmune diseases (e.g. rheumatoid arthritis,
ystemic lupus erythematosus, polymyositis), treatment for
he underlying disease, which can include corticosteroids,
ust be intensiﬁed [3].
Aspirin or NSAIDs remain the (historical) mainstay ofreatment (level of evidence B, class I in the European
uidelines). The treatment is efﬁcient if the drug is used at
n appropriate anti-inﬂammatory dosage (e.g. aspirin 2—4 g
er day, ibuprofen 1600—3200mg per day) for 1—2 weeks.
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fterwards, the optimal length of treatment is debatable
4—8 weeks) and the need for gradual tapering is increas-
ngly proposed [2]. C-reactive protein concentration could
e used as a marker of disease activity to guide treatment
ength [7].
hat is the role for colchicine in this
etting?
eadow saffron bulbs have been used for about 3000 years as
herapeutic agents for gout and constipation, and for their
metic effects. Colchicine was isolated in 1820 and Alfred
oudé was the ﬁrst pharmacist to sell colchicine pills in 1884
n Paris. The compound can be extracted from two plants of
he Lily family: Colchicium autumnale (meadow saffron) and
loriosa superba (glory lily).
The ofﬁcial indication for colchicine is the treatment
nd prevention of gouty attacks but it is also widely used
off label) for treating familial Mediterranean fever and pri-
ary biliary cirrhosis. The exact mechanism of action of the
rug is not fully understood. It shows preferential concen-
ration in white blood cells (more than 16 times the peak
oncentration in plasma), where it reduces the inﬂammatory
esponse. Most of the pharmacological effects seem to be
elated to the capacity of the drug to inhibit the process of
icrotubule self-assembly by binding beta-tubulin with the
ormation of tubulin-colchicine complexes, thus interfering
ith several cellular functions (e.g. chemotoxis, degranu-
ation, phagocytosis) [9]. In this way, colchicine decreases
eucocyte motility and phagocytosis.
Because of the proven efﬁcacy of colchicine in pre-
enting relapses of systemic inﬂammatory processes in
amilial Mediterranean fever (recurrent polyserositis), in
987, Rodriguez de la Serna et al. tested colchicine to pre-
ent recurrences of acute pericarditis in three patients with
P (two idiopathic and one with systemic lupus erythe-
atosus) [10]. Thereafter, several retrospective studies [9]
nvolving 9 to 51 patients seemed to conﬁrm the efﬁciency
f the drug in RP.
In 2005, 1 year after the publication of the European
uidelines on management of pericardial diseases [3], the
esults of two important (but open-label) studies were
ade available. In the CORE (COlchicine for REcurrent
ericarditis) trial [11], 84 patients with a ﬁrst episode
f RP were randomly assigned to receive conventional
reatment with aspirin alone (or corticosteroids when
spirin was contraindicated) or aspirin plus colchicine.
nti-inﬂammatory drugs were given for about 3—5 weeks
progressively tapered) and colchicine (0.5—1mg per day)
or 6 months. The results were impressive: recurrence rates
t 18 months were 50.6% in the conventional treatment
roup vs 24.0% in the conventional treatment plus colchicine
roup (P = 0.022).
The results of the COPE (COlchicine for PEricarditis)
tudy [12] even suggested prescribing colchicine not only
or RP but also at the ﬁrst pericarditis attack. Indeed, in this
rial, 120 patients with a ﬁrst episode of acute pericarditis
ere randomly assigned to conventional treatment with
spirin or conventional treatment plus colchicine for 3
onths. After a mean follow-up of 18 months, the mean
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recurrence rate was reduced from 32.3% (conventional
group) to 10.7% (plus colchicine group) (P = 0.004). These
results conﬁrm those of a preliminary French study of 19
patients published in 1991 [13].
Further studies are required to validate the use of
colchicine for pericarditis. We must be grateful to Imazio
et al. for conducting the CORP, CORP-2 and ICAP studies [14],
which are double-blind, randomized, prospective trials test-
ing colchicine (as adjunct to conventional therapy) in ﬁrst-
attack pericarditis and RP. Results should be available soon.
In the meantime, the results of the COPPS (COlchicine
for the Prevention of the Post-pericardiotomy Syndrome)
study have been recently published [15]: in this double-
blind, placebo-controlled study, colchicine, administered
for 1 month from the third postoperative day as a preven-
tive treatment for postpericardiotomy syndrome (PPS) after
heart surgery seemed to be efﬁcient. However, the PPS def-
inition was imprecise, the number of ‘events’ was therefore
artiﬁcially increased and most were not clinically signiﬁcant.
For instance, only one cardiac tamponade occurred during
the study.
Therefore, whether colchicine could help to reduce the
volume of postoperative pericardial effusions or prevent
the occurrence of tamponades is impossible to predict. The
answer to this question will be given by the results of the
POPE2 (PostOperative Pericardial Effusion 2) study (pro-
moted by the French society of cardiology) in 2013—2014.
For the record, the POPE1 study [16] demonstrated the
absence of efﬁcacy of NSAIDs in this particular situation.
In conclusion, growing evidence suggests that colchicine
may be useful for acute pericarditis, especially when com-
bined with aspirin or an NSAID and particularly to prevent
recurrences, which are the most frequent complication of
this disease. Results of four ongoing double-blind trials will
help deﬁne the indications in ﬁrst-attack pericarditis and RP,
as well as perhaps postoperative pericardial effusions.
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